For some, perhaps getting patents in India just isn’t worth the hassle anymore
Roche announced last week that it is allowing the Indian patent covering its breast cancer treatment Trastuzumab – marketed under the brand name of Herceptin – to expire. If other life sciences companies follow suit and decide that Indian patents…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.